Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Mazdutide

Mazdutide

GLP-1/GCG · s.c. · Innovent (Lilly licence)

Data cut 12 November 2026 · page built 16 November 2026 · 11 trial arms · 6 trials with results · 14 registered trials · see on the pipeline board

Summary

Also known as
IBI362
Mechanism
GLP-1/GCG
Route
s.c.
Company
Innovent (Lilly licence)
Highest development stage
approved
Status (as of data cut)
Approved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026) verify
Next milestone
9 mg approval; GLORY-3 vs semaglutide

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelNMPA (China), June 2025GLORY-1; NMPA approval (Jun 2025)
T2D4 approved / in labelNMPA (China), September 2025NMPA approval (Sep 2025)
CV outcomes2 phase 3 ongoingPhase 3 ongoing
CKD2 phase 3 ongoingPhase 3 ongoing
HFpEF1 phase 2 / signalPhase 2 only
MASH2 phase 3 ongoingPhase 3 ongoing
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA0 no data
Alzheimer's2 phase 3 ongoingPhase 3 in T2D with early cognitive impairment ongoingLIGHT-COG

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
US phase 2 (NCT06124807)3-6 mg (3 mg to week 32)obesity32179−7.3 % vs −0.9 %
Δ −6.4 pp
————————press release
US phase 2 (NCT06124807)10 mgobesity32179−15.6 % vs −0.9 %
Δ −14.7 pp
————————press release
US phase 2 (NCT06124807)16 mgobesity32179−18.1 % vs −0.9 %
Δ −17.2 pp
——20.0—————press release
DREAMS-14 mgt2d china24320—−5.5 % vs −1.1 %
Δ −4.3 pp
−1.6 vs −0.2——————press release
DREAMS-16 mgt2d china24320—−7.3 % vs −1.1 %
Δ −6.2 pp
−2.0 vs −0.2——————press release
DREAMS-2mazdutide 4 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 %t2d china28——−6.5 %−1.62.18.735.524.05.8—verified
DREAMS-2mazdutide 6 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 %t2d china28——−8.5 %−1.73.713.134.429.14.9—verified
DREAMS-36 mg vs semaglutide 1 mg: weight -6.0 %, HbA1c -1.84t2d china32349——−10.3 %
estimand not specified
−2.0——————press release
GLORY-1mazdutide 4 mgobesity china48——−11.0 % vs +0.3 %
Δ −11.3 pp
—1.5 vs 1.011.3 vs 5.432.5 vs 5.926.1 vs 2.95.9 vs 6.3—verified
GLORY-1mazdutide 6 mgobesity china48——−14.0 % vs +0.3 %
Δ −14.3 pp
—0.5 vs 1.010.9 vs 5.450.5 vs 5.943.1 vs 2.94.0 vs 6.3—verified
GLORY-2mazdutide 9 mgobesity china60—−18.6 % vs −3.0 %
Δ −15.5 pp
−16.6 % vs −1.5 %
Δ −15.1 pp
—2.9 vs 0.013.0 vs 5.246.9 vs 3.253.1 vs 1.37.2 vs 5.2−9.8 vs −0.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (44)
  • 3-6 mg (3 mg to week 32) · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 10 mg · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 16 mg · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 16 mg · ae_dc · publication
    discontinuation of study treatment due to adverse events occurred most frequently with 16 mg (20%)
  • 4 mg · hba1c · press release
    the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
  • 4 mg · weight_tp · press release
    the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
  • 6 mg · hba1c · press release
    the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
  • 6 mg · weight_tp · press release
    the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
  • 6 mg · hba1c · press release
    the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group
  • 6 mg · weight_unsp · press release
    the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6.00% in the semaglutide group
  • mazdutide 4 mg · weight_tp · Table 2 (week 48, key secondary end point)
    | Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
  • mazdutide 4 mg · ae_dc · Table 4
    | Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5)
  • mazdutide 4 mg · disc_any · Results, Participants, paragraph 1
    trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
  • mazdutide 4 mg · nausea · Table 4
    | Nausea | 66 (32.5)
  • mazdutide 4 mg · vomiting · Table 4
    | Vomiting | 53 (26.1)
  • mazdutide 4 mg · sae · Table 4
    | Serious adverse event | 12 (5.9)
  • mazdutide 6 mg · weight_tp · Table 2 (week 48, key secondary end point)
    | Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
  • mazdutide 6 mg · ae_dc · Table 4
    | Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5) | 1 (0.5)
  • mazdutide 6 mg · disc_any · Results, Participants, paragraph 1
    trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
  • mazdutide 6 mg · nausea · Table 4
    | Nausea | 66 (32.5) | 102 (50.5)
  • mazdutide 6 mg · vomiting · Table 4
    | Vomiting | 53 (26.1) | 87 (43.1)
  • mazdutide 6 mg · sae · Table 4
    | Serious adverse event | 12 (5.9) | 8 (4.0)
  • mazdutide 9 mg · weight_eff · Results, Coprimary Outcomes, paragraph 1 (eTable 1 in Supple
    the mean percentage change in body weight from baseline to week 60 was -18.55% (95% CI, -19.78% to -17.31%) in the mazdutide group vs -3.02% (95% CI, -4.72% to -1.31%) in the placebo group
  • mazdutide 9 mg · weight_tp · Table 2; Results, Coprimary Outcomes, paragraph 1
    mean percentage change in body weight from baseline to week 60 was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group vs -1.50% (95% CI, -3.43% to 0.43%) in the placebo group
  • mazdutide 9 mg · ae_dc · Table 3
    | Any that led to treatment discontinuation | 9 (2.9) | 0 | 2.9 (0.5 to 5.5) |
  • mazdutide 9 mg · disc_any · Results, Participants; Figure 1
    89.6% of participants (267 [87.0%] in the mazdutide group vs 146 [94.8%] in the placebo group) completed the treatment
  • mazdutide 9 mg · nausea · Table 3
    | Nausea | 144 (46.9) | 5 (3.2) | 43.7 (37.1 to 49.7) |
  • mazdutide 9 mg · vomiting · Table 3
    | Vomiting | 163 (53.1) | 2 (1.3) | 51.8 (45.7 to 57.5) |
  • mazdutide 9 mg · sae · Table 3
    | Serious adverse eventsa | 22 (7.2) | 8 (5.2) | 2.0 (-3.3 to 6.3) |
  • mazdutide 9 mg · sbp · Results, Key Secondary Outcomes, paragraph 2; Table 2 (garbl
    systolic blood pressure was -9.80 mm Hg (95% CI, -11.37 to -8.23 mm Hg) in the mazdutide group vs -0.23 mm Hg (95% CI, -2.13 to 1.67 mm Hg) in the placebo group
  • mazdutide 4 mg · weight_tp · Results, Body weight paragraph 1; Table 2
    with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
  • mazdutide 4 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
    TEAEs that led to study treatment discontinuation occurred in five (2.1%) participants who received 4 mg mazdutide
  • mazdutide 4 mg · disc_any · Fig. 1 (trial profile)
    N6[242 received at least one dose] --> N9[21 discontinued study treatment: Adverse event: 5 br Withdrawal by participant: 16]
  • mazdutide 4 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    nausea (35.5%, 34.4% and 17.1%)
  • mazdutide 4 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    vomiting (24.0%, 29.1% and 14.3%)
  • mazdutide 4 mg · sae · Results, Safety paragraph 1; Table 3
    adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
  • mazdutide 4 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
    mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
  • mazdutide 6 mg · weight_tp · Results, Body weight paragraph 1; Table 2
    with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
  • mazdutide 6 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
    nine (3.7%) who received 6 mg mazdutide and four (1.6%) who received 1.5 mg dulaglutide (Table 3 and Extended Data Table 2)
  • mazdutide 6 mg · disc_any · Fig. 1 (trial profile)
    N7[244 received at least one dose] --> N12[32 discontinued study treatment: Adverse event: 9 br Withdrawal by participant: 22 br Physician decision: 1]
  • mazdutide 6 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    nausea (35.5%, 34.4% and 17.1%)
  • mazdutide 6 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    vomiting (24.0%, 29.1% and 14.3%)
  • mazdutide 6 mg · sae · Results, Safety paragraph 1; Table 3
    adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
  • mazdutide 6 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
    mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)

Registered trials (14)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
HypertensionPhase 3recruiting2026-04 → 2026-08336recruitingNCT07469800
NCT07255209 · China
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
ObesityPhase 3recruiting2025-12 → 2027-10180recruitingNCT07255209
LIGHT-COG Study
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Alzheimer'sPhase 3recruiting2025-09 → 2029-08420recruitingNCT07083154
GLORY-OSA
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Sleep apnoeaPhase 3recruiting2025-06 → 2027-05260recruitingNCT06931028
NCT06937749
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MASHPhase 2active not recruiting2025-06 → 2026-09181active not recruitingNCT06937749
GLORY-3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
MASHPhase 3active not recruiting2025-05 → 2026-12479active not recruitingNCT06884293
NCT06862908
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
HFpEFPhase 2active not recruiting2025-03 → 2026-09141active not recruitingNCT06862908
NCT06817356
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
AddictionPhase 2completed2025-02 → 2026-03308Completed; results not in the atlas yetNCT06817356
NCT06519656
Efficacy of Mazdutide for Treating PCOS
OtherPhase 2completed2024-10 → 2026-0943Completed; results not in the atlas yetNCT06519656
DREAMS-3
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
ObesityPhase 3completed2024-02 → 2025-09349Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06184568
GLORY-2
A Study of IBI362 9 mg in Chinese Adults With Obesity
ObesityPhase 3unknown2023-12 → 2025-06462unknownNCT06164873
DREAMS-2
A Study of IBI362 in Participants With Type 2 Diabetes
T2DPhase 3completed2023-01 → 2024-01731Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05606913
NCT05628311 · China
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
T2DPhase 3completed2023-01 → 2023-10319Completed; results not in the atlas yetNCT05628311
GLORY-1
A Study of IBI362 in Participants With Obesity or Overweight
ObesityPhase 3completed2022-11 → 2023-08610Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05607680

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Mazdutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/mazdutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.